{"id":"mifepristone-plus-one-dose-misoprostol","safety":{"commonSideEffects":[{"rate":"95-100","effect":"Vaginal bleeding/heavy bleeding"},{"rate":"80-90","effect":"Abdominal pain/cramping"},{"rate":"50-70","effect":"Nausea"},{"rate":"20-30","effect":"Vomiting"},{"rate":"20-30","effect":"Diarrhea"},{"rate":"10-20","effect":"Dizziness"},{"rate":"10-20","effect":"Headache"},{"rate":"5-10","effect":"Fever/chills"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mifepristone is a progesterone antagonist that prevents the hormone from maintaining the uterine lining and pregnancy. Misoprostol, a prostaglandin analog, is then administered to stimulate uterine contractions and facilitate expulsion of pregnancy tissue. Together, this combination achieves medical abortion through complementary mechanisms.","oneSentence":"Mifepristone blocks progesterone receptors to stop pregnancy development, followed by misoprostol to induce uterine contractions and expel pregnancy tissue.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:21:30.468Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Medical abortion (termination of intrauterine pregnancy up to 10 weeks gestation)"}]},"trialDetails":[{"nctId":"NCT05839899","phase":"PHASE3","title":"Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location","status":"UNKNOWN","sponsor":"Planned Parenthood League of Massachusetts","startDate":"2023-08-30","conditions":"Abortion","enrollment":50},{"nctId":"NCT05046041","phase":"PHASE4","title":"Assessing Outpatient 'Day Procedure' for Second-trimester Medical Abortion at Two Public Sector Hospitals in Nepal","status":"COMPLETED","sponsor":"Gynuity Health Projects","startDate":"2020-11-25","conditions":"Abortion in Second Trimester","enrollment":120},{"nctId":"NCT03829696","phase":"PHASE4","title":"Advance Provision of Medication Abortion","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2020-01","conditions":"Early Abortion","enrollment":""},{"nctId":"NCT03346629","phase":"PHASE4","title":"Outpatient Service for Mid-trimester Termination of Pregnancy","status":"COMPLETED","sponsor":"Gynuity Health Projects","startDate":"2017-12-01","conditions":"Abortion in Second Trimester","enrollment":230},{"nctId":"NCT01768299","phase":"PHASE4","title":"Medical Abortion With Mifepristone + Misoprostol (13 - 22 Weeks)","status":"COMPLETED","sponsor":"Gynuity Health Projects","startDate":"2013-02","conditions":"Complete Uterine Evacuation After Use of Study Drugs","enrollment":504}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Mifepristone plus one dose Misoprostol","genericName":"Mifepristone plus one dose Misoprostol","companyName":"Planned Parenthood League of Massachusetts","companyId":"planned-parenthood-league-of-massachusetts","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mifepristone blocks progesterone receptors to stop pregnancy development, followed by misoprostol to induce uterine contractions and expel pregnancy tissue. Used for Medical abortion (termination of intrauterine pregnancy up to 10 weeks gestation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}